Independent Conference Highlights of the 2022 ASH Annual Meeting*

The combination of CPX-351 and midostaurin showed manageable toxicity and suggested promising efficacy in patients with newly diagnosed AML and either a FLT3 ITD or TKD mutation.

In a nonrandomized cohort analysis of adult patients with high-risk BCP-ALL, those who received blinatumomab during consolidation had improved clinical outcomes, including a higher MRD rate, lower incidence of relapse, and longer disease-free survival.

Adding inotuzumab ozogamicin to induction therapy resulted in a high response rate and promising 2-year survival in older patients with newly diagnosed CD22+ B-lymphoblastic leukemia.

Venetoclax + azacitidine showed ongoing OS benefit vs azacitidine monotherapy in patients with newly diagnosed AML ineligible for intensive chemotherapy with an additional 2 years of follow-up.

This triplet combination demonstrated encouraging activity in frontline AML, with high CR/CRi rates in patients with TP53^wt and TP53^mut AML.

After 5 years of follow-up, low-dose dasatinib at 50 mg daily continued to be both effective and safe in newly diagnosed CML-CP.

Phase I dose-finding study reports that treatment with revumenib, a menin inhibitor, resulted in a clinically manageable safety profile and deep, durable responses in patients with KMT2A or NPM1 acute leukemia.

Current phase Ia/Ib analysis reports manageable safety and preliminary efficacy with ziftomenib in patients with relapsed/refractory AML, with a CR rate of 30% in 20 patients with NPM1-mutated disease.

Addition of asciminib to imatinib led to higher rate of DMR vs continued imatinib or switch to nilotinib in patients with chronic-phase chronic myeloid leukemia not achieving DMR with ≥1 year of imatinib therapy.

Updated results from a phase I/II trial of gilteritinib in combination with azacitidine/venetoclax show high CR rates and MRD negativity in frontline and relapsed/refractory FLT3-mutated AML.

Consolidation therapy with blinatumomab plus chemotherapy confers a significant OS benefit compared with consolidation chemotherapy alone in adult patients with MRD-negative BCR::ABL1-negative B-lineage acute lymphoblastic leukemia.